Based on these findings, various tyrosine kinase inhibitors targeting VEGF, EGRF or FGF receptors such as sorafenib, sunitinib, regorafenib, etc. are under clinical trials for different types of tumor [37–39]. Here, VEGFA is linked to neoplasm.